27 December 2017 - - The global point-of-care infectious disease diagnostics/testing market is expected to reach USD 1.90bn by 2025, according to a report from Dublin-based Research and Markets.

An emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth.

The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings.

A rise in the investments for R and D and development of new products is expected to spur progress in this market through to 2025.

For instance, development of a new lab-on-a-disc' technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment.

This allows precise drugs administration thus influencing adoption rate.

HIV POC is estimated to account for the largest share owing to the rising incidence of this disease.

Advances in the bio sensing technology for the early detection with sensitivity is expected to fuel revenue generation in the coming years.

Moreover, companies are engaged in embracing a quality management approach for the introduction of novel tests for HIV diagnosis.

TB and drug resistant TB is anticipated to witness lucrative demand in the coming years as a result of rise in the incidence rate of drug resistance TB.

Demand for the development of inexpensive, rapid, simple, and accurate tests that are able to detect multiple biomarkers simultaneously is expected to boost progress.
Implementation of fully or partially integrated nano/microscale technologies in developing DR-TB diagnostic devices is anticipated to fuel progress in the segment.

Clinics accounted for the largest revenue share owing to the higher usage of rapid testing kits in clinics.

North America dominates the space with adequate administration support, well-established healthcare framework, and extensive research and technology upgradation.

Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support.

Key players in this market include Alere, BD and Co, Cardinal Health,Bio-Rad Labs Inc.,bioMrieux SA, Chembio Diagnostics Inc,Trinity Biotech, F. Hoffmann-La Roche Ltd, OJ-Bio Ltd, Ortho-Clinical Diagnostics, Quest Diagnostics Inc, Siemens Healthineers, Sight Diagnostics Ltd.,Gene POC, Thermo Fisher Scientific Inc and Trivitron Healthcare.